Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Completes Acquisition of HalioDx
Fuels growth by enabling IVD test development and manufacturing for nCounter diagnostic platform Expands scientific capabilities into immuno-oncology and broadens diagnostics scope to 8 of the 10 top cancers by U.S. incidence SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug.
View HTML
Toggle Summary Veracyte Announces Second Quarter 2021 Financial Results
Total Revenue Increased 166% to $55.1 million ; Genomic Volume Grew 215% to 20,856 Tests Company Advanced Clinical Evidence, Pipeline and Global Growth Strategy Raises 2021 Total Revenue Guidance Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul.
View HTML
Toggle Summary New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
Real-world data suggest Decipher test’s risk scores are independently associated with conversion to definitive treatment and with treatment failure SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 27, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data suggesting the Decipher ®
View HTML
Toggle Summary Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 12, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. Chambers , a seasoned financial executive with a track
View HTML
Toggle Summary Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Thursday, July 29 . Company management will host a conference call and webcast to
View HTML
Toggle Summary Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
Rob Brainin Named Executive Vice President and Chief Business Officer; Bill Zondler Appointed Senior Vice President and Chief Information Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced key
View HTML
Toggle Summary Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 1, 2021-- Veracyte (Nasdaq: VCYT), a global genomic diagnostics company, today announced key appointments that expand and further strengthen the company’s medical team. William A. Bulman , M.D. and Paul Kelly Marcom , M.D, have joined the company
View HTML
Toggle Summary New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
First study demonstrating Decipher Prostate test can inform treatment decisions in nmCRPC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the prognostic utility of the company’s Decipher ® Prostate genomic
View HTML
Toggle Summary Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
First Molecular Subtyping Test to Gain Medicare Coverage to Inform Treatment for Individuals With Bladder Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Medicare Administrative Contractors Palmetto GBA, WPS and CGS
View HTML
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Details of the Raymond James Human Health Innovation Conference have been corrected. The updated release reads: VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company,
View HTML